SFM
NMRA icon

Soros Fund Management’s Neumora Therapeutics NMRA Stock Holding History

Soros Fund Management’s Portfolio NMRA Stock Details NMRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-10,000
Closed -$141K – 257
2023
Q3 		$141K Buy
+10,000
New +$125K ﹤0.01% 208

Other funds holding NMRA

SoftBank Group
SoftBank Group Tokyo, Japan $11.4B AUM 27.91% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
MCMU
MIC Capital Management (UK) London, United Kingdom $352M AUM 0.23% 1-Year Est. Return
IC
Iconiq Capital San Francisco, California $4.46B AUM 22.86% 1-Year Est. Return
WT
Wellcome Trust London, United Kingdom $9.01B AUM 12.05% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $652M AUM 198.07% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Soros Fund Management's NMRA Position: Q4 2023 in Review

Soros Fund Management sold out of Neumora Therapeutics (NMRA) in Q4 2023, closing a stake of 10,000 shares — an estimated $141K sold.

Soros Fund Management first reported a position in NMRA in Q3 2023 and held it in 1 quarter. The position peaked at $141K in Q3 2023. 60 funds tracked by Wall St. Rank hold NMRA as of Q4 2023.

  • Soros Fund Management reported no remaining Neumora Therapeutics position as of Q4 2023 after selling out during the quarter.
  • Soros Fund Management sold 10,000 Neumora Therapeutics shares in Q4 2023, an estimated $141K.
  • Soros Fund Management first reported a position in Neumora Therapeutics in Q3 2023 and held it in 1 quarter.
  • Soros Fund Management's Neumora Therapeutics position peaked at $141K in Q3 2023.
  • 60 funds tracked by Wall St. Rank held Neumora Therapeutics as of Q4 2023.

Based on Soros Fund Management's 13F filing for Q4 2023, filed 14 Feb 2024.